SAN DIEGO, Jan. 27, 2011 /PRNewswire/ — Profil™ Institute
for Clinical Research, Inc., a company leading the industry in
early phase clinical trials for diabetes and obesity, announced
today that CEO Dr. Marcus Hompesch is an invited speaker at the
Ramanbhai Foundation 5th International Symposium and ISCR’s 4th
Annual Clinical Research Conference in February.
The Ramanbhai Foundation’s International Symposium will be held
February 1-4 in Ahmedabad, India and is hosted by the Zydus
Research Center, the research arm of Indian pharmaceutical company
Zydus Cadila. The symposium’s speakers include world-leading
scientists from academia and the pharmaceutical industry
specializing in drug research and development for cancer,
inflammation, and cardio-metabolic diseases. Profil
Institute’s Dr. Hompesch will speak on the topic of selecting the
appropriate target populations for early phase clinical research
and first in human studies of diabetes drugs.
Dr. Hompesch will also present at the Indian Society for
Clinical Research’s (ISCR) 4th Annual Clinical Research Conference
held February 11-12 at the Crowne Plaza Hotel in Gurgaon, India.
The conference’s focus is strengthening India’s domestic
clinical research industry through best practices, stricter
regulatory standards and global partnerships. Dr. Hompesch
will present on the topic of early clinical development in India
and its proof of concept in diabetes.
“Historically India’s pharmaceutical companies have focused on
providing outsourcing and on competitive manufacturing of generics,
APIs, and chemicals used in the manufacturing of drugs,” said Dr.
Marcus Hompesch, Profil Institute CEO. “However, healthcare
has become a key priority for the Indian government, and we are now
seeing a paradigm shift as India strives to bolster its position in
the pharmaceutical and clinical research industry as a global
partner, innovator and competitor.”
India’
‘/>”/>
